Pursuant to Regulation 30 of SEBI (LODR) Reg. 2015, find enclosed herewith the copy of investor presentation in connection with the Audited Standalone & Consolidation Financial Results ....
NATCAPSUQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Natural Capsules reported Q4FY26 consolidated revenue of Rs 58.45 Cr (up 55% QoQ, 30% YoY), driven by dispatch of goods deferred from Q3 due to Puducherry plant shutdown. However, EBITDA collapsed to Rs 1.33 Cr with margins at just 2.28%, and the company posted a net loss of Rs 4.98 Cr for the quarter. For full year FY26, revenue grew 11% to Rs 187.20 Cr but the company recorded a net loss of Rs 24.66 Cr versus profit of Rs 0.62 Cr in FY25, with EBITDA margins turning negative at -0.83%. The managing director stated that FY27 is expected to be a "stable year" with focus on capacity utilization and operational efficiency. Commercial API sales have commenced, and a new HPMC capsule line is ready but revenue impact expected from H2 FY27. A new CDMO collaboration was signed with Fermbox Bio for the Tumkur fermentation facility.
The sharp deterioration in FY26 profitability, with full-year EBITDA turning negative, is a significant concern for shareholders despite Q4 recovery. The company faces margin pressure from its new API segment (lower margin profile acknowledged by management) and elevated finance costs (up 73% YoY to Rs 10.95 Cr). Recovery depends on successful scaling of the API business and higher-margin regulated market approvals.